Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial
Related Posts
Kellner DA, Dente E, Tran V, Welsh T, Tran V, Saha A, Baker JF, Elashoff DA, Ranganath VK. Effect of Glucagon-Like Peptide 1 Receptor Agonists[...]
Demographics and Trends of Sudden Cardiac Death-Related Mortality in the United States, 1999 to 2022
Jaiswal V, Kumar D, Mashkoor Y, Latif F, Kanagala SG, Halder A, Jaiswal A, Bandyopadhyay D, Hajra A, Joshi A, Aronow WS, Fonarow GC. Demographics[...]
Scheideman AF, Shao MM, Zelada H, Cuadros J, Foreman J, Sarder P, Ho C, Ejskjaer N, Fleischer J, Cichosz SL, Armstrong DG, Mathioudakis N, Wang[...]